Fig. 5: The immune landscape of the high-risk and low-risk patients in multiple melanoma cohorts.

Significant differential of 29 immune signatures scores from He et al. (a) and Bagaev et al. (b) estimated by the ssGSEA method between low-risk and high-risk patients across melanoma cohorts. c The proportions of high immune and low immune infiltration estimated by 29 immune signatures from He et al. in the high-risk and low-risk melanoma patients. The P values were computed by Fisher’s exact test. d Significant differential of correlation coefficients among 29 immune signatures from He et al. between high-risk and low-risk patients in TCGA SKCM dataset. e Significant differential immune signatures score from Thorsson et al. between high-risk and low-risk melanoma patients. Significant differential expression of chemokines (f), MHC (g), co-inhibitors (h), and co-stimulators (i) genes between low-risk and high-risk patients across melanoma cohorts. The P values were calculated from one-sided Wilcoxon rank-sum test with FDR-adjusted. Fold change (FC) values were calculated by ratio of mean gene expression from low-risk and high-risk patients. For P value, * denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001.